{"id":5321,"date":"2025-09-20T13:32:18","date_gmt":"2025-09-20T09:32:18","guid":{"rendered":"https:\/\/medscriptum.org\/?p=5321"},"modified":"2025-09-20T13:40:50","modified_gmt":"2025-09-20T09:40:50","slug":"innovative-molecular-target","status":"publish","type":"post","link":"https:\/\/medscriptum.org\/en\/innovative-molecular-target\/","title":{"rendered":"Innovative Molecular Target in the Management of Acute Megakaryoblastic Leukemia: A Study from Yale University"},"content":{"rendered":"

At Yale University, researchers have thoroughly investigated the mechanism underlying the development of aggressive blood cancer, Acute Megakaryoblastic Leukemia (AMKL).<\/span><\/p>\n

Scientists have discovered that a mutant protein, RBM15-MKL1, formed through a gene fusion, plays a critical role in the progression of the disease. It disrupts the process of N6-methyladenosine (m6A) modification, which affects gene expression and the behavior of specific RNAs. This discovery brings us closer to a better understanding of this rare form of leukemia and the development of targeted therapies.<\/span><\/p>\n

Acute Megakaryoblastic Leukemia (AMKL) is an aggressive subtype of Acute Myeloid Leukemia (AML), characterized by the proliferation of immature blood cells. The disease primarily affects children and is associated with a severe clinical course. Despite advances in hematology, there is still no effective and specific therapy for AMKL. Current treatment regimens are marked by high toxicity and limited applicability, making the management of this leukemia a significant challenge in modern medicine. To address this, researchers at Yale University conducted an in-depth study and identified that the mutant fusion protein RBM15-MKL1 can bind to RNA and alter its function, promoting the growth and spread of cancer cells. Laboratory experiments revealed that this mutant protein activates the Wnt signaling pathway\u2014a pathway closely linked to cancer development. Specifically, RBM15-MKL1 regulates \u2018Frizzled\u2019 proteins, which are critical components of Wnt signaling. By suppressing the activity of these proteins, researchers were able to significantly inhibit the proliferation of leukemic cells in laboratory animals. Furthermore, the same study led to the development of an experimental compound that reduces Wnt signaling. In preclinical trials, this agent effectively eradicated leukemia cells in mice.<\/span><\/p>\n

The research team believes that various forms of AMKL may share a common mechanism of development\u2014dependence on the Wnt signaling pathway\u2014which could ultimately enable scientists to develop more targeted and less toxic therapies:<\/span><\/p>\n

Our study highlights the importance of translational science,” says Dr. Giulia Biancon, former member of the Hallen Lab at the Yale Cancer Center. “We developed models of AMKL to investigate RNA-related alterations and demonstrated that these changes can be corrected using small-molecule inhibitors with anti-cancer properties.<\/span><\/p>\n

The lead authors of the study\u2014Dr. Toma Tebaldi, <\/span>Arthur H, Isabel Bunker<\/span> and Stephanie Halene \u2014report that targeted therapies focusing on m6A modification and Wnt signaling are already undergoing clinical trials and may one day be used to treat this rare and aggressive leukemia in children.<\/span><\/p>\n

Source:<\/p>\n

Yale School of Medicine<\/span><\/a><\/p>\n

Tebaldi, T., H., A., Bunker, I., & Halene, S. (2025). <\/span>Innovative Molecular Target in the Management of Acute Megakaryoblastic Leukemia: A Study from Yale University<\/span><\/i> [Preprint]. bioRxiv. <\/span>https:\/\/doi.org\/10.1101\/2025.02.19.638991v1<\/span><\/a>.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

At Yale University, researchers have thoroughly investigated the mechanism underlying the development of aggressive blood cancer, Acute Megakaryoblastic Leukemia (AMKL). Scientists have discovered that a mutant protein, RBM15-MKL1, formed through a gene fusion, plays a critical role in the progression of the disease. It disrupts the process of N6-methyladenosine (m6A) modification, which affects gene expression […]<\/p>\n","protected":false},"author":6,"featured_media":5320,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1594],"tags":[1970,1971,1879,1874],"class_list":["post-5321","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","tag-hematology","tag-lymphoma","tag-research","tag-kvleva"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/5321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=5321"}],"version-history":[{"count":1,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/5321\/revisions"}],"predecessor-version":[{"id":5322,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/5321\/revisions\/5322"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/5320"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=5321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=5321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=5321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}